Vertex taps a team player to take over as CMO during a big transition at the top
Incoming Vertex CEO Reshma Kewalramani has selected her replacement as CMO, choosing to promote a member of the R&D team to the post. Carmen Bozic, who joined the company last May from Biogen, has been named EVP, Global Medicines Development and Medical Affairs today and gets to add the new title of CMO next April as Vertex cautiously transfers the reins to a new CEO who will have lots to do winning over some skeptical analysts.
There’s another promotion in the works today at Vertex. Nia Tatsis, Vertex’s SVP, global regulatory affairs, is taking over as head of regulatory, effective immediately.
Bozic’s first job at Vertex was leading clinical development of the company’s cystic fibrosis and alpha-1 antitrypsin deficiency programs, as well as “leading clinical operations across the pipeline, among other areas.” Prior to joining Vertex, Bozic spent more than 20 years at Biogen, which is seeing its top R&D exec depart today.
Once the moves are complete, Vertex will have a balanced gender mix on the top team, with women holding top titles in the company — a rare profile in Big Biotech.
Vertex has established itself as the leading company in CF drug development under CEO Jeffrey Leiden, far out in front of any rivals to the throne. In the past year, it’s also been making some bold moves to acquire potentially curative therapies, which has had a mixed reaction on Wall Street. Investors don’t always appreciate heavy risk, though the past few years have seen the most aggressive players swinging for the fences.